← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Collaborations Pharmaceuticals, Inc.
Fuquay Varina, NC
$25,010,316
Total funding
22
Grants
Funding over time
peak $8.2M · FY2016–25$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,059,688 · 20
DOD$2,950,628 · 2
By mechanism
R44$10,040,079 · 4
SB1$3,953,139 · 1
—$2,950,628 · 2
N44$1,999,195 · 1
R43$1,943,234 · 7
R42$1,729,534 · 1
Investigators at Collaborations Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
USING MACHINE LEARNING AND IN VITRO METHODS TO ASSESS HUMAN METABOLISM OF ORGANOPHOSPHATES PESTICIDES AND CHEMICAL WARFARE AGENTS$2,754,147
· FY2025 · Defense Threat Reduction Agency
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease$2,112,893
SB1 · FY2025 · NS
Discovery and Development of Oral Small-molecule Direct-acting Antivirals$1,999,195
N44 · FY2025 · AI
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease$1,840,246
SB1 · FY2024 · NS
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease$1,499,923
R44 · FY2022 · NS
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease$1,499,923
R44 · FY2023 · NS
Machine learning approaches to predict Acetylcholinesterase inhibition and model applications$1,317,335
R44 · FY2025 · ES
MegaTrans â human transporter machine learning models$864,767
R42 · FY2023 · GM
MegaTrans â human transporter machine learning models$864,767
R42 · FY2022 · GM
Centralized assay datasets for modelling support of small drug discovery organizations$855,127
R44 · FY2021 · GM
MegaTox for analyzing and visualizing data across different screening systems$855,003
R44 · FY2023 · ES
MegaTox for analyzing and visualizing data across different screening systems$855,003
R44 · FY2022 · ES
Centralized assay datasets for modelling support of small drug discovery organizations$854,677
R44 · FY2022 · GM
Machine learning approaches to predict Acetylcholinesterase inhibition and model applications$727,312
R44 · FY2024 · ES
Centralized assay datasets for modelling support of small drug discovery organizations$694,172
R44 · FY2018 · GM
Centralized assay datasets for modelling support of small drug discovery organizations$692,845
R44 · FY2019 · GM
Repurposing pyronaridine as a treatment for Chagas disease$313,687
UH2 · FY2017 · TR
Repurposing pyronaridine as a treatment for the Ebola virus$312,390
R21 · FY2017 · TR
Repurposing pyronaridine as a treatment for Chagas disease$300,277
UH2 · FY2018 · TR
Preclinical development of a Nipah Virus inhibitor$295,096
R43 · FY2023 · AI